Riskpilot← Back to searchSign inGet full accessALPHA BIOTECH AB
ABActiveOrg 5566168703UppsalaResearch and experimental development on natural sciences and engineering · NACE 7210Est. 20010 employees
Revenue 2024
SEK 51K
-50% vs 2023
EBITDA margin
-24.8%
-127% vs 2023
Equity ratio
-1.2%
Financial strength
Net profit 2024
SEK -292K
-1493% vs 2023
| Revenue | SEK 51K | -50% |
| EBITDA | SEK -13K | -127% |
| Net profit | SEK -292K | -1493% |
| Total assets | SEK 967K | -21% |
| Equity | SEK -11K | -104% |
| Employees | 0 | — |
Legal name
ALPHA BIOTECH AB
Org number
5566168703
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
3 oktober 2001
Share capital
SEK 277 100
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas ensam av Nilsson, Lennart Kenneth
Company purpose
Bolaget skall idka forsknings-, konsultations-, innovations- och produktionsverksamhet inom det medicinskt, tekniskt, ekonomiska fältet och därmed förenlig verksamhet.
Address
Uppsala
Email
info@alphabiotech.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 87 | 103 | 62 | 103 | 51 |
| Staff expenses | — | — | — | — | −0 |
| EBITDA | −103 | 10 | 6 | 47 | −13 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | — |
| EBIT | −103 | 10 | 6 | 47 | −13 |
| Net financials | −34 | −33 | −31 | −27 | −280 |
| Profit before tax | −137 | −23 | −25 | 21 | — |
| Tax | −0 | −0 | −0 | −0 | — |
| Net profit | −137 | −23 | −25 | 21 | −292 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 1 211 | 1 252 | 1 225 | 1 228 | 967 |
| Equity | 308 | 285 | 260 | 281 | −11 |
| Long-term debt | 206 | 270 | 269 | 224 | 235 |
| Short-term debt | 696 | 698 | 696 | 723 | 744 |
| Total debt | 902 | 968 | 965 | 947 | 979 |
EBITDA margin
-24.8%
This company
15.8%
Market median
-257% vs market
20202024
Equity ratio
-1.2%
This company
38.2%
Market median
-103% vs market
20202024
Return on equity
-29242700.0%
This company
18.4%
Market median
-158927817% vs market
20202024
Net profit margin
-568.4%
This company
8.1%
Market median
-7117% vs market
20202024
Asset turnover
0.05×
This company
1.12×
Market median
-96% vs market
20202024
Debt / equity
86.32×
This company
0.62×
Market median
-13823% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
OÅ Audit | Audit | 2020 |
| Name | Role | Member since |
|---|---|---|
| Current (4) | ||
| Board of Directors | 2020 | |
| Board of Directors | 2020 | |
| Chairman | 2020 | |
| Board of Directors | 2020 | |
| Former (2) | ||
| Board of Directors | 2020 – 2022 | |
| Deputy Board Member | 2020 – 2020 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of ALPHA BIOTECH AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Ola Åke Axel Asplund | Audit | 0 companies |
| Jan-Anders Christer Mellberg | Board of Directors | 0 companies |
| Carl Robert Raynald Pålsson | Board of Directors | 0 companies |
| Per Jan Erik Karlsson | Board of Directors | 0 companies |
| Lennart Kenneth Nilsson | Chairman | 0 companies |
| Malik Stephan Merza | Board of Directors | 0 companies |
| Sten Olof Folke Lindquist | Deputy Board Member | 0 companies |